Image For Activity Cover
2020 Annual Global Meeting: Virtual
Fully virtual event, held September 10-13, 2020 
Course includes master and plenaries sessions, see information for sessions below. 
Speaker & Presentation Information
Master Session: Cervix Cancer
Kathleen Moore  Histologic Subtypes & Molecular Features
Jalid Sehouli  Staging
Alexandra Taylor State of the Science in Radiation Therapy:
Linda Mileshkin Addition Systemic Therapy to Radiation
Leslie Randall Firstline Treatment of Metastatic Disease
Krishnansu Tewari Second-Line Metastatic Disease
Marie Plante Clinical Care in Under-Resourced Settings & How To Start A Clinical Trials Program

Master Session: Ovarian Cancer
Martin Koebel How to Subclassify Ovarian Carcinoma into Hystotypes & Molecular Subtypes?
Sven Mahner  TRUST Update
Dennis Chi NACT Proponent: Anna Fagotti (Italy); PDS Proponent
Robert Coleman Vignette Presentation
David O’Malley HRD Positive
Shannon Westin  HRP BRCA Neg
Rosalind Glasspool  Platinum Sensitive Recurrence at 12 Months: What’s next? Who Benefits from PARP in the Recurring Setting?
Charlie Gourley  Molecular Testing for Initial Therapy; Beyond BRCA
Brad Nelson Biomarkers for Immunotherapy Response

Master Session: Uterine Cancer
Edward Tanner Sentinel LN is Positive on Frozen Section: Full Dissection vs "Why did I Send for Frozen?
Emma Rossi  Sufficient Evidence to Implement SLN in Women with EC, High Risk Histology - Risk of Missing Paraaortic LN Metastases
Andrea Mariani Case Set Up with Controversy
Marie Plante What to do with ITC and Micro Metastasis in SLN on Final Pathology
Floor Backes No Need for Adjuvant Treatment or Send for the Chemo & Radiation? Or in the Middle?
Jessica McAlpine & Remi Nout Debate: Molecular Profiling for Postop Risk Stratification & Adjuvant Treatment Decisions of Women with Early Stage EC
Mansoor Mirza Where are We Today & Where are We Going in the Treatment of Women with Advanced/Recurrent EC?

Master Session: Vulvar Cancer
Joanne de Hullu Current Insights in the Etiology & Pathogenesis of Vulvar Cancer: HPV Infection - Predisposing Conditions - Premalignant Disease - Overt Malignancy
Maaike Oonk & Nadja Dornhöfer Debate: Early Stage Vulvar Cancer: An Overview of Current Standard of Surgical Care vs Cancer Field Surgery for Vulvar Carcinoma as Alternative Approach
Linn Wölber Role of Adjuvant Therapy in Primary Treatment of Vulvar Cancer

Plenary I: Oral Abstract Presentation
Jonathan Ledermann Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial
Antonio González-Martín Efficacy and Safety of Lenvatinib Plus Pembrolizumab in Patients with Previously Treated Ovarian Cancer in the Multicohort Phase 2 LEAP-005 Study
Johanne Weberpals  Postprogression Efficacy Outcomes From the Phase 3 ARIEL3 Study of Rucaparib in Patients With Platinum-Sensitive Recurrent Ovarian Carcinoma Associated With Either BRCA1 or BRCA2 Mutations
Kathleen Moore Distillation

Plenary II: Oral Abstract Presentation
Emily Thompson Refining Pathologic Interpretation of Endometrial Carcinomas: Lessons Learned from a Nationwide Study in a new Era of Molecular Classification
Soyoun Rachel Kim Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study
Emily Thompson Variation in practice in endometrial cancer (EC); can molecular classification direct care and reduce costs associated with management?
Maria Cusimano  Sentinel lymph node biopsy versus lymphadenectomy for intermediate and high grade endometrial cancer staging (SENTOR trial): A prospective multicenter cohort study
Salvatore Gueli Alletti A multicentric randomized trial to evaluate the ROle of uterine MANipulator on laparoscopic/robotic HYsterectomy for the treatment of low-risk endometrial cancer: the ROMANHY Trial (NCT:02762214)
Morcos Nakhla  Frailty is Independently Associated with Worse Outcomes and Increased Resource Use Following Procedures to Treat Endometrial Cancer

Plenary III: Oral Abstract Presentations
Isle Baeten The learning curve of robot-assisted laparoscopy has impact on the oncological outcomes of early stage cervical cancer patients
Andrea Mariani Oncologic Outcomes and Role of Adjuvant Therapy in Endometrial Cancer Patients with Low Volume Metastasis in the Sentinel Lymph Nodes: An International Multi-Institutional Study
Robert Holloway Oncolytic Vaccinia (Olvi-Vec) Primed Immunochemotherapy in Platinum Resistant/Refractory Ovarian Cancer
Whitney Graybill Efficacy on Individualized Starting Dose (ISD) and Fixed Starting Dose (FSD) of Niraparib per Investigator-Assessment (IA) in Newly Diagnosed Advanced Ovarian Cancer (OC)
Asima Mukhopadhyay Distillation

Presidential Plenary IV
Roberto Angioli Presidential Address
Elisabeth Baugh  World Ovarian Cancer Coalition Global Ovarian Cancer Charter Launch
Dicey Jackson Scroggins Global Outreach & Engagement Initiatives of the International Gynecologic Cancer Society
Roberto Angioli Business Meeting

Plenary V: Oral Abstract Presentations
Nobumichi Nishikawa Phase II trial evaluating efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
Rodney Rocconi  Randomized Double-Blind Placebo Controlled Trial of Frontline Maintenance Vigil Immunotherapy (VITAL study) in Stage III/IV Ovarian Cancer: Efficacy Assessment in BRCA1/2-wt Patients
Angeles Alvarez Secord Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer: Angeles Alvarez Secord (USA)
Gilles Freyer Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
Philipp Harter Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higherand lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial
Member Benefit
This course is an IGCS member benefit.

Not an IGCS member? Join IGCS today and be a part of the leading global society advancing gynecologic cancer care around the world. In addition to complimentary valuable educational resources and training opportunities, you will also be supporting the society’s mission to enhance the care of women with gynecologic cancer worldwide through education and training and public awareness. Click here to learn more about IGCS member benefits.
Availability: On-Demand
Cost: FREE
Contact for assistance.
Powered By